Details of the Drug Reposition

General Information of This Drug (ID: DMF30HL)

• Drug Name: Zarnestra (DMF30HL)
• Synonyms: JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute myeloid leukaemia	DIS0BM1I	2A60	Phase 3	[1]

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Human papillomavirus infection	DISX61LX	1A9Y	Phase 2	[2]
Chronic myelogenous leukaemia	DIS0301E	2A20.0	Phase 2	[2]
Myelodysplastic syndrome	DISYHNUI	2A37	Phase 2	[2]
Peripheral T-cell lymphoma	DISCDT4E	2A90.C	Phase 2	[2]

2 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Colorectal cancer	DISNH7P9	2B91.Z	Phase 1/2	[3]
Pancreatic cancer	DISJC981	2C10	Phase 1/2	[3]

References

• [1] ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.